INTRODUCTION

HIV Treat Bull - 2008 May-June;9(5/6):10

In this issue of HTB, we continue our extended coverage of this important meeting (see previous two issues of HTB for earlier reports.

The reports in this issue covers timing of HAART, treatment access, women’s health and paediatric care and include:

• Immediate HAART reduces death and AIDS progression over 48 weeks in patients with acute OIs
• Utility of routine viral load, CD4 count and clinical monitoring among HIV-positive adults in rural Uganda
• Implementation of more complex regimens for prevention of mother-to-child transmission of HIV in Rwanda
• The estimated cost of switching from d4T to TDF in South Africa
• Gender differences in viral load by CD4 count in men and women
• Immune reconstitution inflammatory syndrome in young children initiating ART
• Complications with BCG vaccination in HIV-positive and negative infants: CHER Study
• The association between clinical characteristics and HIV-infection in very young infants
• Safety and efficacy of boosted darunavir in treatment-experienced children and adolescents at 24 weeks
• Responses to atazanavir-containing HAART in treatment-naïve children in South Africa
• Initial growth, CD4, and viral load responses to HAART in Ugandan compared to UK/Irish HIV-positive children
• Paediatric pharmacokinetic studies
• A pilot study of three treatment strategies for HIV-positive infants

Abstracts for the meeting are online as soon as the conference opens, and many of the most important oral abstract sessions and overview sessions are posted as webcasts within a day or so. We encourage readers to go directly to the source for many of these sessions.

http://www.retroconference.org

2008-05-10
IB080905-07

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.